Ischemic Heart Disease (IHD) Drugs Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the Ischemic Heart Disease (IHD) Drugs market right now?
In recent times, the market for ischemic heart disease (IHD) medications has seen significant growth. From $6.36 billion in 2024, it is projected to surge to $6.71 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. The expansion during the historic period stems from a rise in worldwide cases of ischemic heart disease, improved awareness and diagnostic measures, modifications in lifestyle and diet habits, governmental strategies for heart health, partnership for clinical trials, and policies for insurance coverage and reimbursement.
How fast Is the ischemic heart disease (ihd) drugs market expected to grow, and what’s its future value?
The market for drugs treating ischemic heart disease (IHD) is forecasted to experience consistent expansion in the coming years, positioning it at $7.86 billion in 2029 with an annual compound growth rate (CAGR) of 4.0%. Several factors are influencing this growth during the projection period such as the aging global population, the introduction of personalized medicine, increased stress on cardiovascular prevention, the implementation of worldwide health policies and initiatives, and partnerships in international research. Noteworthy trends during this prediction period will encompass a transition towards precision medicine methods, an enhanced focus on innovative anti-atherogenic agents, improvements in therapies lowering lipid levels, the inclusion of anti-inflammatory agents, and the invention of antithrombotic and antiplatelet drugs.
Get your ischemic heart disease (ihd) drugs market report here!
What are the leading drivers of growth in the ischemic heart disease (ihd) drugs market?
Anticipated growth in the ischemic heart disease (IHD) drugs market is correlated to an increasing global prevalence of obesity and diabetes. These two health conditions, one responsible for dangerously excessive body fat and the other, a chronic metabolic disease causing high blood glucose levels, significantly impact the cardiovascular health. Consequently, IHD drugs have become a common method to manage associate risk factors like hypertension and dyslipidemia, thereby reducing the chance of ischemic heart disease. For example, the UK-based World Obesity Federation predicts that by 2030, one billion people worldwide will be obese, including a fifth of all women and a seventh of all men. Furthermore, in 2024, UK’s National Health Service reported that the number of individuals in England identified as at risk of developing type 2 diabetes has risen to more than half a million (549,000) in 2023. This brings the total of those with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330, representing an almost 20% increase from 3,065,825 in 2022. Therefore, the escalating rates of obesity and diabetes worldwide are contributing to the growth of the ischemic heart disease (IHD) drugs market. Rising cases of heart failure are another driving force for the growth of the ischemic heart disease (IHD) drug market. Heart failure, a chronic condition rendering the heart muscle unable to pump enough blood to meet the body’s oxygen and blood needs, often causes fatigue, shortness of breath, and difficulty performing everyday tasks. IHD drugs are instrumental in treating heart failure by lowering heart disease risk factors and symptoms and preventing the onset of heart failure. IHD drugs also hinder the heart’s pacemaker activity, providing benefits to heart failure patients with reduced ejection fractions and high resting heart rates, after a tolerated beta-blocker. An insight from the Heart Failure Society of America in September 2023 reveals that over 6.7 million Americans above 20 years old have heart failure (HF), and this figure is likely to reach 8.5 million by 2030. This suggests a growing link between increasing cases of heart failure and the growth of the ischemic heart disease (IHD) drug market.
What are the key segments defining the ischemic heart disease (ihd) drugs market?
The ischemic heart disease (IHD) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
Who are the key players steering the development of the ischemic heart disease (ihd) drugs market?
Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC
What emerging trends are influencing the growth of the ischemic heart disease (ihd) drugs market?
Key players in the ischemic heart disease (IHD) drugs market, such as Bristol Myers Squibb, are turning their attention towards the creation of novel myosin inhibitors as a means of enhancing their position in the market. These drugs work by curbing the activity of myosin in heart muscle, thereby reducing the force of contractions. This is particularly helpful in treating conditions such as hypertrophic cardiomyopathy (HCM), where the thickening of the heart muscle adversely affects its functionality. For instance, in April 2022, Bristol Myers Squibb introduced Camzyos (mavacamten), the first-ever approved cardiac myosin inhibitor designed for adults suffering from symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy (HCM). This medication enhances functional capacity and alleviates symptoms by acting as an allosteric and reversible inhibitor selective for cardiac myosin, decreasing hypercontractility and left ventricular hypertrophy and ameliorating cardiac filling pressures. These actions lead to a reduction in dynamic left ventricular outflow tract (LVOT) obstruction.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13467
Which regions are most influential in expanding the ischemic heart disease (ihd) drugs market?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Narcotic Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/narcotic-drugs-global-market-report
Preeclampsia Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report
Congenital Diaphragmatic Hernia Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
